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Abstract
Osteosarcoma is the most common primary high-grade bone tumor in both adolescents and children. Early tumor
detection is key to ensuring effective treatment. Serum marker discovery and validation for pediatric osteosarcoma
has accelerated in recent years, coincident with an evolving understanding of molecules and their complex
interactions, and the compelling need for improved pediatric osteosarcoma outcome measures in clinical trials. This
review gives a short overview of serological markers for pediatric osteosarcoma, and highlights advances in
pediatric osteosarcoma-related marker research within the past year. Studies in the past year involving serum
markers in patients with pediatric osteosarcoma can be assigned to one of four categories, i.e., new approaches
and new markers, exploratory studies in specialized disease subsets, large cross-sectional validation studies, and
longitudinal studies, with and without an intervention.
Most of the studies have examined the association of a serum marker with some aspect of the natural history of
pediatric osteosarcoma. As illustrated by the many studies reviewed, several serum markers are emerging that
show a credible association with disease modification. The expanding pool of informative osteosarcoma-related
markers is expected to impact development of therapeutics for pediatric osteosarcoma positively and, it is hoped,
ultimately clinical care. Combinations of serum markers of natural immunity, thyroid hormone homeostasis, and
bone tumorigenesis may be undertaken together in patients with pediatric osteosarcoma. These serum markers in
combination may do better. The potential effect of an intrinsic dynamic balance of tumor angiogenesis residing
within a single hormone (tri-iodothyronine) is an attractive concept for regulation of vascularization in pediatric
osteosarcoma.
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Introduction
Osteosarcoma is the most prevalent malignant bone
tumor [1]. Accounting for 30%-80% of the primary skeletal
sarcomas, it is the most common of all bone malignancies
[2]. The population affected is predominantly children,
teenagers, and young adults aged 10-30 years [3]. Males
are more affected than females. Osteosarcomas predomi-
nantly target the long cylindrical bones, including the knee
joint (approximately half of the observations) and the
humerus [4]. Among the most affected are the femur,
tibia, and humerus. The tumor is less frequently localized
in the shoulder blade, pelvic, and skull bones [5]. Typically,
osteogenetic sarcomas metastasize early into the lungs,
and metastases to lymph nodes are found in isolated cases
[6,7].
Today’s leading researchers, pharmacy and biotechnol-
ogy decision-makers, technology companies, and clini-
cians are focusing on the use of serum tumor markers in
the field of pediatric osteosarcoma research. The search
for serum tumor markers for early detection and diagno-
sis of pediatric osteosarcoma has been a daunting task
which has been met with little success. Much of the
research effort in the past has been centered on discovery
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and characterization of single markers [8-10]. A marker
is applicable as a fluid analyte when at least two require-
ments are met, i.e., the potential marker must circulate in
the serum and a quantitative high-throughput assay must
be available to detect the marker.
As a rule, the types of cancer that develop in children are
different from the types that are found in adults. Various
international osteosarcoma study groups, including the
Cooperative German-Austrian-Dutch Osteosarcoma,
National Osteosarcoma Etiology, North American Develop-
ments in Osteosarcoma, European American Osteosar-
coma, Scandinavian Sarcoma, and North American
Children’s Oncology groups, have agreed on trying to con-
duct a collaborative tumor marker study [11-16]. The
power of such collaboration lies in the ability to conduct
large research projects for studying pediatric osteosarcoma.
This paper gives an overview of established and experi-
mental serological markers in the diagnosis of pediatric
osteosarcoma. We have focused exclusively on osteosar-
coma in the younger age group. This review summarizes
mainly the prognostic values of classical and novel mar-
kers for pediatric osteosarcoma.
Serum tumor marker discovery offers hope of new
pediatric osteosarcoma test
A wide variety of serological markers have been asso-
ciated with pediatric osteosarcoma (Table 1). These may
be broadly divided into several groups. Markers are most
commonly grouped by chemical structure or by the
biological function they have in the organism [17-19].
Chemically, markers can be divided into glycoproteins,
polypeptides, carbohydrate determinants of glycopro-
teins, glycolipids, proteins, polyamines, and immunoglo-
bulins [20-23]. In terms of biological function, markers
can be divided into oncofetal antigens, enzymes, hor-
mones, receptors, and compounds with an as yet unclear
function [24-26]. Tumor markers involved in angiogen-
esis, cell adhesion, apoptosis, and the cell cycle have been
shown recently to play an important role in osteosarcoma
growth, differentiation, and metastasis [27-30]. Over the
coming years, the new markers may be able not only to
prognosticate pediatric osteosarcoma patients at baseline
but also to serve as therapeutic targets and thereby
further improve survival rates [31-33]. No osteosarcoma-
specific marker, more particularly pediatric osteosar-
coma-specific marker, has been found thus far, so where
lies the future of pediatric osteosarcoma biomarker
research?
Free polyamines
One known method of diagnosing cancer is to use free
polyamines as biochemical tumor markers in children’s
osteosarcoma [34]. Tumor development is accompanied
by disorders of polyamine metabolism, spurring their
intensive release from cells into biological fluids (blood
and urine). Based on this, the level of free polyamines is
measured in blood sera and blood-formed elements.
Their levels in children with osteosarcoma were found to
exceed reference values in 92.4% of cases for formed ele-
ments and 63% for plasma [35]. Following tumor surgery,
58% of children showed a decrease in polyamine count.
The data suggest that measurement of free polyamines in
blood-formed elements on a background of cancer can
be used before treatment as an informative indicator of a
malignant process. The fact that removal of tumor local-
ity fails to normalize polyamine levels in up to half of
cases points to the shortcomings of this method when
the polyamine level has to be used in treated patients to
test for recurrence.
Insulin-like growth factor-1 and insulin-like growth factor
binding protein-3
Preclinical work has suggested a role of insulin-like growth
factor-1 (IGF-1) in the proliferation of osteosarcoma cells
in vivo [36]. This research group has addressed the rela-
tionship between serum levels of IGF-1, its binding protein
(IGFBP-3), and the clinical behavior and outcome of
osteosarcoma in children. In a retrospective study of 37
patients, it was found that circulating levels of IGF-1 and
IGFBP-3 were not predictive of the development or clini-
cal characteristics of pediatric osteosarcoma. However,
further studies in a larger patient population should be
performed in order to investigate this relationship further.
Monoclonal antibody of circulating tumor-associated
antigen ki67
A prognostication method in children’s osteosarcoma
using ki67 monoclonal antibodies is known. Using these
antibodies, Petrosyan et al [37] found that the mean bind-
ing index in bone sarcomas is 9.7% and markedly exceeds
the same parameter in benign bone neoplasms. The
expression of this antigen has been shown to correlate
with the extent of biological tumor activity and the clinical
course of the disease. However, studies into the possibility
of using this indicator as a prognostic test preceding recur-
rences have not been conducted, rendering its application
in this respect impossible at present.
TNF-b and soluble TNF receptor
Kotz et al [38] determined serum levels of tumor necrosis
factor beta (TNF-b) and soluble TNF receptor in pediatric
patients with highly malignant primary bone tumors. Both
TNF-b and soluble TNF receptor levels were lower in
serum from pediatric osteosarcoma patients as compared
with those with Ewing’s sarcoma. In patients with high-
grade osteosarcoma, but not Ewing’s sarcoma, high levels
of TNF-b correlated with a bad response to neoadjuvant
chemotherapy. In patients with high-grade osteosarcoma,
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TNF-b levels seem to be of predictive value, and both
TNF-b and soluble TNF receptor levels seem to be of
diagnostic value for differentiation between high-grade
osteosarcoma and Ewing’s sarcoma in children.
Markers of bone formation and resorption
In adolescent patients with bone sarcoma, bone mass
acquisition is potentially compromised at a time when it
should be at a maximum [39]. To evaluate this problem,
the authors measured bone mineral density and serum
markers of bone formation and resorption in a series of
pediatric patients with bone tumors [40]. Ruza et al [41]
analyzed 85 samples from 59 patients with osteosarcoma
and 54 samples from 36 patients with Ewing’s sarcoma.
Serum markers of bone formation (procollagen type I C-
terminal propeptide and osteocalcin) and resorption (car-
boxyterminal telopeptide) were lower than reference
values throughout. Significant alterations in other markers
were also observed. Up to one third of patients with osteo-
sarcoma and Ewing’s sarcoma in clinical remission had
some degree of bone mineral density deficit. The corre-
sponding increased risk in pathologic bone fractures her-
alds a reduction in future quality of life.
Tri-iodothyronine
The functional condition of different components of the
endocrine system undergoes certain changes during the
malignant process. In several situations, it was determined
that an impaired hormonal balance can have a central role
in the pathogenesis of tumoral transformation in the tis-
sues. This suggests that the search for dynamic deviations
in levels of biologically active compounds developing dur-
ing the premanifestation stage needs to be conducted for
hormonal indicators, in particular indicators of thyroid
homeostasis, since it is the thyroid hormones that, unlike
other hormones, have the widest range of biological activ-
ity, including regulating the main stages of all metabolic
processes in the organism, affecting proliferation speed
and nervous and immune system function, the status of
which, in turn, largely determines resistance of the
Table 1 List of candidate serum markers for pediatric osteosarcoma and their possible clinical utility.
Serum
marker





POS development is accompanied by disorders of polyamine metabolism
spurring their intensive release from cells into biological fluids






IGF-1/IGFBP-3 levels correlate with the presence of metastatic disease,
histologic response, event-free survival
Promising predictive factor of







Increased levels anti-ki57 antibody associated with extent of biological
activity of tumor and clinical course of POS




In high-grade POS, high levels of TNF-b correlated with bad response to
neoadjuvant chemotherapy
Marker for monitoring of response to
neoadjuvant chemotherapy in POS
Holzer et al [38]
ANG Expression of ANG correlates with an increase in local density of blood
vessels in tumor tissue, with development of pulmonary metastasis and
poor prognosis







Decreased production of PICP, OC, ICTP associated with bone metabolism
in POS








CD44 No significant difference was observed between serum CD44 levels of
children with sarcoma and healthy children
Serum CD44 levels were not found to
be of value in diagnosis or prognosis
for POS
Kebudi et al [43]
VEGF Increased VEGF levels correlates with tumor stage and disease-free
survival
Prognostic factor in POS Koznetsova et al
[85]
SAA Increased SAA levels associated with type of tumor and high-risk POS
development
Differentiates malignant bone cancer
from benign bone tumors and detects
POS in high-risk children
Krizkova et al
[44]
BALP Increased BALP levels associated with development of POS Marker for late detecting, monitoring,






Increased CXCL4, CXCL6, and CXCL12 levels associated with poor disease-
free survival




Analysis of cytokine concentration showed large statistically significant
differences between POS and control group for IL-4 and IL-8
Markers for individual reaction of
organism to the development of POS
Markiewicz et al
[24]
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organism to malignancy [42]. A method of predicting pro-
cess generation in children and adolescents with osteosar-
coma useful for comprehensive tumor treatment and
biochemical study. One distinctive feature is that after
comprehensive treatment resulting in a complete clinical
and laboratory remission, the patient’s blood is tested for
the free fraction of tri-iodothyronine thyroid hormone. A
level of 4.0-5.2 pmol/mL predicts remission of 6-24
months, while a level of 5.8-7.4 pmol/mL points to genera-
tion of the malignant process in 1-3 months. The assess-
ment makes it possible to use free T3 in the blood after
treatment as an additional laboratory indicator to assess
the future course of the disease and to initiate appropriate
treatment in a timely fashion.
CD44
Kebudi et al [43] compared serum CD44 levels in children
having sarcomas with those in healthy children. There was
no statistically significant difference between serum CD44
levels in children with sarcomas and those in healthy chil-
dren. There was no significant difference between serum
CD44 levels according to stage or outcome. In this study,
serum CD44 levels were not found to be of diagnostic or
prognostic value for osteosarcoma in children.
Amyloid protein A
Using proteomic profiles, the authors constructed a multi-
variate three-nearest neighbor classifier to distinguish
pediatric osteosarcoma from osteochondroma patients
with a sensitivity of 97% and a specificity of 80% based on
external leave-one-out cross-validation [44]. One of the
proteins in the proteomic signature was identified as
serum amyloid protein A. Classification based on this
plasma proteomic signature may be useful to differentiate
malignant bone cancer from benign bone tumors and for
early detection of osteosarcoma in high-risk children.
Bone alkaline phosphatase
Osteosarcoma usually develops in young children [45].
While the incidence of osteosarcoma increases steadily
with age, a relatively dramatic increase in adolescence cor-
responds with the growth spurt [46]. This is good reason
to suggest a link between the blastomatic process and the
bone growth spurt, as well as sports and other physical
activities. Biochemical markers of bone turnover reflecting
the intensity of the bone remodeling process in the skele-
ton are important for fast and noninvasive assessment of
bone formation and resorption processes [47]. They can
be used in terms of both physiological and pathological
states. An elevated level of serum bone alkaline phospha-
tase, which is found in more than 40% of osteosarcoma
patients, is also a valuable diagnostic parameter [48]. How-
ever, due to the difficulties in general standardization, this
parameter may be difficult to interpret in younger patients.
Ambroszkiewicz et al showed that bone turnover markers,
especially bone alkaline phosphatase, may be useful in the
monitoring and assessment of treatment efficacy in chil-
dren’s osteosarcoma [49].
CXC chemokines
Li et al [50] used an antibody microarray to identify che-
mokines that were elevated in serum samples of pediatric
osteosarcoma patients. The results demonstrated that
CXCL4 and CXCL6 are frequently expressed in osteosar-
coma, and that plasma levels of these two chemokines are
associated with patient outcomes. Further study of these
circulating chemokines may provide a promising approach
for prognostication of pediatric osteosarcoma.
Cytokines
Causes of osteosarcoma are still unknown and the reaction
of the immune system to its development is very indivi-
dual. Particular emphasis must be placed on the role of
cytokines in immunoregulatory and coordinating func-
tions and tumor cell disruption. Knowledge about cytokine
concentrations in serum, with regard to mechanisms of
oncogenesis, may have prognostic significance for the
further course of osteosarcoma in children. In a study that
evaluated interleukin (IL)-2, IL-4, IL-8, interferon (IFN)-g,
and TNF-a concentrations at the time of diagnosis in chil-
dren with osteosarcoma, the following concentrations of
peripheral blood cytokines were observed: IL-2 10.7 pg/
mL, IFN-g 1.3 pg/mL, TNF-a 28.3 pg/mL, IL-4 2.0 pg/mL,
and IL-8 13.5 pg/mL [51]. Results of studies obtained at
diagnosis did not give a specific answer about the prog-
nosis and further course of osteosarcoma in patients
according to age. Big differences in cytokine concentra-
tions in children and youth with osteosarcoma might be
associated with individual biological variations and indivi-
dual reactions to the development of neoplastic disease.
Further studies in this direction are needed before the
start of cytostatic therapy and therapeutic monitoring of
cytostatic therapy.
Angiogenin
The relevance of neoangiogenesis (formation of new blood
vessels) in malignant tumors is not in doubt, because
tumors cannot develop without forming an extensive
capillary network to ensure the performance of their vital
functions [52,53]. A critical step in the development of
osteosarcoma is hematogenous metastasis [54]. The aver-
age dissemination time does not usually exceed 8-12
months. The results of many study confirm the suggestion
that angiogenin plays a key role in hematogenous metasta-
sis [55]. The development of angiogenin-dependent angio-
genesis and the growth of small blood vessels increases
the chances of tumor cells entering the circulation,
because the newly formed small capillaries with a
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fragmented basal membrane are much easier for the
tumor cells to pass through than larger vessels [56]. In
addition, a large number of small vessels have a larger sur-
face through which tumor cells metastasize quickly. Corre-
lation between the angiogenin level in the blood and the
presence of metastasis, as well as the timing of metastasis,
appears to have prognostic significance in osteosarcoma
patients [57]. Thus, the expression of angiogenin in pri-
mary osteosarcoma correlates with an increase in the local
density of blood vessels in tumor tissue, with the develop-
ment of metastatic pulmonary disease and a poor prog-
nosis [58]. It may be possible to use angiogenin as a
marker for predicting metastasis in pediatric osteosarcoma
patients. This is important due to the fact that diagnostic
errors, as experience shows, are fairly common.
A study by Kreuter et al assessed osteosarcoma tumori-
genesis in pediatric patients treated on the basis of micro-
vessel density and vascular endothelial growth factor
expression [59]. No differences in the extent of angiogen-
esis were seen in relation to treatment outcome or pre-
sence of metastasis. However, studies like this are scarce
and the results are not always accurate.
Biomarker-IgM immune complexes
Natural antibodies are hallmark components of anticancer
activity [60,61]. Natural antibodies have multiple roles in
the immune system, [62] and appear to maintain B cell
homeostasis, clear apoptotic cells, and protect against
autoimmunity. All tumor-specific antibodies belong
almost exclusively to the IgM class [63]. Human serum
contains natural antibodies, which are present prior to the
development of cancer [64]. During the first phase of this
process, i.e., the primary immune response, IgM is the spe-
cific antibody produced [65].
In contrast with the detection of serum tumor angio-
genesis antigens, the detection of natural serum antibo-
dies to tumor angiogenesis antigens may provide reliable
serum markers for early diagnosis and prognosis in
pediatric osteosarcoma [66,67]. Tumor-associated natural
IgM antibodies circulate in the blood much earlier than
serum antigens [68,69]. Natural IgM antibodies to tumor
antigen have been reported in patients with early-stage
cancer, and a panel of serum antibodies can detect cancer
5 years prior to radiographic detection [70,71]. Biomar-
ker-IgM immune complexes are a novel class of serum
tumor markers with greater diagnostic potential than the
corresponding free markers.
The advantage of this approach is that it should be pos-
sible to detect the full range of heterogenous osteosarco-
mas by increasing the number of angiogenin-IgM assays
or altering the antigens used in the natural IgM antibodies
panel. Circulating immune complexes formed by tumor
antigens and IgM represent a novel class of serum tumor
markers with diagnostic value for early detection of
osteosarcoma. Measuring natural antibodies to angiogen-
esis bioregulators could become an additional method for
early diagnosis of pediatric osteosarcoma. Analysis of the
work done to date will allow the physician to assess the
health status of a child objectively, to obtain data on possi-
ble risk groups based on selected criteria and initiate pre-
vention efforts in a timely manner. Studies in these areas
have become the basis of a new research direction for
comprehensive study of immune status in children [72].
Maintenance of angiogenin-IgM may also be an important
aspect of osteosarcoma tumorigenesis and could be linked
to prognosis. It is thus reasonable to increase the range of
classical markers using in practice by adding such novel
prognostic markers as angiogenin-IgM.
Potential use of serum tumor markers for early detection,
diagnosis, and prevention
We do not know what causes children to develop bone
tumors. Only about two in every 10 children who develop
malignant bone tumors have a family history of the condi-
tion [73]. Children aged 6-12 years are the age group most
likely to develop benign bone tumors, although the tumors
sometimes show up in children as young as two years of
age [74]. Osteosarcoma usually begins when children are
young teenagers [75]. This is a time when their bones are
growing very rapidly and they are often taking part in
sports and other physical activities [76]. The most com-
mon age at which children are diagnosed with these
cancers is 14 years [77].
Progress in the fields of biochemistry, molecular biology,
and biotechnology has allowed researchers and clinicians
to use biologically significant indicators to assist in pre-
dicting early osteosarcoma in children and in choosing
appropriate therapy when the disease is advanced. The
future of pediatric osteosarcoma markers must involve a
more molecular approach to the measurement of relevant
clinical prognostic factors and the development of treat-
ments based on the molecular profile of tumors.
The specificity of an individual tumor marker is quite
low, but increases when several markers are used in com-
bination [78,79]. The accuracy of studies of tumor markers
is contingent on their sensitivity and specificity [80-83].
Markers can be major, minor, and additional [84]. A
major marker is one with high sensitivity and specificity
for a certain type of tumor [85]. Minor markers are typi-
cally measured in parallel with measurement of the major
marker [86]. Minor markers have lower tumor sensitivity
and specificity in comparison with the major marker.
When used in conjunction with the major marker, a
minor marker increases the probability of detecting a
tumor. Additional markers are generally more sensitive to
the disease than minor markers, but can be specific to a
particular organ. In addition, the increase in marker levels
is associated with tumor recurrence [87].
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Because osteosarcoma is heterogeneous, we suggest
measuring all three types of markers at the beginning of
treatment (marker of natural immunity as major, marker
of thyroid hormone status as minor, and marker of bone
tumor angiogenesis as additional). The triple test is an
investigation to classify a pediatric patient as either high-
risk or low-risk for osteosarcoma. An understanding of
the balance between, bone tumor angiogenesis, and thyr-
oid hormone status may assist in diagnostics and thera-
peutics for children with osteosarcoma. The potential
effect of an intrinsic dynamic balance of tumor angiogen-
esis residing in a single hormone is an attractive concept
for regulation of vascularization in osteosarcoma. A posi-
tive test in children indicates a high risk of developing
osteosarcoma.
Discussion
The following conclusions (Table 1) can be drawn after
analyzing the data on the significance of serum tumor
markers for diagnosing pediatric osteosarcoma (early
diagnosis, differential diagnosis, early detection of recur-
rence and metastasis), monitoring (assessment of extent
of tumor, choice of adequate therapy, evaluating effec-
tiveness of treatment) and prognosis [88-92]:
● So far no specific diagnostic preparation has been
developed capable of detecting a malignant tumor of
a certain histological type (pediatric osteosarcoma)
and locating it at the earliest possible stages of
formation.
● No universal and specific serum tumor markers
have been found for early diagnosis of pediatric
osteosarcoma and primary screening in risk groups.
● Several markers can be used successfully for the
diagnosis of osteosarcoma in children.
● Most of the characterized markers are used for
monitoring, while some are employed for the predic-
tion of pediatric osteosarcoma.
● Although initial expectations concerning sensitivity
and specificity of individual serum markers have not
been fulfilled, a rational approach to these tests and
balanced interpretation of the results make them
clinical significant.
● The number of serum markers for diagnosing
osteosarcoma is growing, which poses the question
of differentiating between them, performing complex
multivariate analysis of diagnostic tests pathognomo-
nic for osteosarcoma, the use of discriminant vari-
ables, which will optimize the examination plans for
individual patients, monitoring, and giving a
prognosis.
We must acknowledge that, despite the presence of a
broad range of tumor markers for the diagnosis and
monitoring of pediatric osteosarcoma, so far no unequi-
vocal system has been developed for introducing these
markers into clinical practice. Based on analysis of the
current state of the problem of using tumor markers for
primary diagnosis and monitoring in children’s osteosar-
coma, schemes have been developed for the most effec-
tive and appropriate serum markers. These schemes
include nonspecific tumor-induced and tumor-produced
markers with high specificity and sensitivity that have
been found suitable for topical diagnosis. Introduction of
biochemical tests for diagnosis and monitoring should be
decided at the international level with regard to equip-
ment in laboratories. Nonspecialized laboratories tasked
with surveying the patient for diagnosis, in particular the
identification of pathology, can be advised to use simple,
affordable systems for nonspecific markers [93-95].
The clinical significance of individual serum osteosar-
coma markers has been widely debated. Despite the fact
that the relevance of these markers is being checked
constantly, some of them are used in clinical practice.
The importance of individual tumor markers need not
be overstated, since they are only an additional diagnos-
tic tool with limited applicability and diagnostic accu-
racy. Improving their diagnostic accuracy requires an
individual therapeutic approach to each patient. Formu-
lation of an individual approach is largely determined by
the choice of tactics based on knowledge of the major
factors influencing the course of the disease. Numerous
international studies conducted using univariate and
multivariate analysis revealed a number of prognostic
factors in osteosarcoma.
Serum tumor markers seemed to be ideal for early diag-
nosis of cancer. However, the lack of sensitivity and speci-
ficity has been a major problem in the use of most serum
tumor markers for diagnosis of pediatric osteosarcoma. In
the vast majority of research studies over the past two dec-
ades, only combination of major (natural immunity),
minor (thyroid hormone status), and additional (bone
tumor angiogenesis) markers has been applied as a “gold
standard” for monitoring and diagnosis of pediatric osteo-
sarcoma patients. Recent advances in knowledge concern-
ing the molecular biology of pediatric osteosarcoma will
hopefully result in serum tumor markers.
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